MovDisordV3, PubMed, Checkpoint, bibRecord, 000109

Presynaptic effects of levodopa and their possible role in dyskinesia.

Identifieur interne : 000109 ( PubMed/Checkpoint ); précédent : 000108; suivant : 000110

Presynaptic effects of levodopa and their possible role in dyskinesia.

Auteurs : Eugene V. Mosharov [États-Unis] ; Anders Borgkvist ; David Sulzer

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.

RBID : pubmed:25450307

English descriptors

KwdEn :
- Animals, Dopamine (metabolism), Dopamine Agents (adverse effects), Dyskinesia, Drug-Induced (etiology), Dyskinesia, Drug-Induced (metabolism), Dyskinesia, Drug-Induced (pathology), Humans, Levodopa (adverse effects), Neurons (cytology), Neurons (drug effects), Parkinson Disease (drug therapy), Presynaptic Terminals (drug effects), Presynaptic Terminals (metabolism).
MESH :
- chemical , adverse effects : Dopamine Agents, Levodopa.
- chemical , metabolism : Dopamine.
- cytology : Neurons.
- drug effects : Neurons, Presynaptic Terminals.
- drug therapy : Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- metabolism : Dyskinesia, Drug-Induced, Presynaptic Terminals.
- pathology : Dyskinesia, Drug-Induced.
- Animals, Humans.

Abstract

Levodopa replacement therapy has long provided the most effective treatment for Parkinson's disease (PD). We review how this dopamine (DA) precursor enhances dopaminergic transmission by providing a greater sphere of neurotransmitter influence as a result of the confluence of increased quantal size and decreased DA reuptake, as well as loading DA as a false transmitter into surviving serotonin neuron synaptic vesicles. We further review literature on how presynaptic dysregulation of DA release after l-dopa might trigger dyskinesias in PD patients.

DOI: 10.1002/mds.26103
PubMed: 25450307

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000334
to stream PubMed, to step Curation: 000334

Links to Exploration step

pubmed:25450307

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Presynaptic effects of levodopa and their possible role in dyskinesia.</title>
<author><name sortKey="Mosharov, Eugene V" sort="Mosharov, Eugene V" uniqKey="Mosharov E" first="Eugene V" last="Mosharov">Eugene V. Mosharov</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Neurology, Columbia University Medical Center, New York, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology, Columbia University Medical Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Borgkvist, Anders" sort="Borgkvist, Anders" uniqKey="Borgkvist A" first="Anders" last="Borgkvist">Anders Borgkvist</name>
</author>
<author><name sortKey="Sulzer, David" sort="Sulzer, David" uniqKey="Sulzer D" first="David" last="Sulzer">David Sulzer</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25450307</idno>
<idno type="pmid">25450307</idno>
<idno type="doi">10.1002/mds.26103</idno>
<idno type="wicri:Area/PubMed/Corpus">000334</idno>
<idno type="wicri:Area/PubMed/Curation">000334</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000109</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Presynaptic effects of levodopa and their possible role in dyskinesia.</title>
<author><name sortKey="Mosharov, Eugene V" sort="Mosharov, Eugene V" uniqKey="Mosharov E" first="Eugene V" last="Mosharov">Eugene V. Mosharov</name>
<affiliation wicri:level="2"><nlm:affiliation>Departments of Neurology, Columbia University Medical Center, New York, New York, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology, Columbia University Medical Center, New York, New York</wicri:regionArea>
<placeName><region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Borgkvist, Anders" sort="Borgkvist, Anders" uniqKey="Borgkvist A" first="Anders" last="Borgkvist">Anders Borgkvist</name>
</author>
<author><name sortKey="Sulzer, David" sort="Sulzer, David" uniqKey="Sulzer D" first="David" last="Sulzer">David Sulzer</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Dopamine (metabolism)</term>
<term>Dopamine Agents (adverse effects)</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Dyskinesia, Drug-Induced (metabolism)</term>
<term>Dyskinesia, Drug-Induced (pathology)</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Neurons (cytology)</term>
<term>Neurons (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Presynaptic Terminals (drug effects)</term>
<term>Presynaptic Terminals (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Neurons</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurons</term>
<term>Presynaptic Terminals</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Presynaptic Terminals</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Levodopa replacement therapy has long provided the most effective treatment for Parkinson's disease (PD). We review how this dopamine (DA) precursor enhances dopaminergic transmission by providing a greater sphere of neurotransmitter influence as a result of the confluence of increased quantal size and decreased DA reuptake, as well as loading DA as a false transmitter into surviving serotonin neuron synaptic vesicles. We further review literature on how presynaptic dysregulation of DA release after l-dopa might trigger dyskinesias in PD patients.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25450307</PMID>
<DateCreated><Year>2015</Year>
<Month>02</Month>
<Day>02</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>09</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2015</Year>
<Month>06</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>30</Volume>
<Issue>1</Issue>
<PubDate><Year>2015</Year>
<Month>Jan</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Presynaptic effects of levodopa and their possible role in dyskinesia.</ArticleTitle>
<Pagination><MedlinePgn>45-53</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26103</ELocationID>
<Abstract><AbstractText>Levodopa replacement therapy has long provided the most effective treatment for Parkinson's disease (PD). We review how this dopamine (DA) precursor enhances dopaminergic transmission by providing a greater sphere of neurotransmitter influence as a result of the confluence of increased quantal size and decreased DA reuptake, as well as loading DA as a false transmitter into surviving serotonin neuron synaptic vesicles. We further review literature on how presynaptic dysregulation of DA release after l-dopa might trigger dyskinesias in PD patients.</AbstractText>
<CopyrightInformation>© 2014 International Parkinson and Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mosharov</LastName>
<ForeName>Eugene V</ForeName>
<Initials>EV</Initials>
<AffiliationInfo><Affiliation>Departments of Neurology, Columbia University Medical Center, New York, New York, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Borgkvist</LastName>
<ForeName>Anders</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sulzer</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P01 DA010154</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P50 NS038370</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 DA007418</GrantID>
<Acronym>DA</Acronym>
<Agency>NIDA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 NS075222</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01NS075222</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>12</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2012 Jun 1;211:13-27</RefSource>
<PMID Version="1">22465440</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurodegener Dis. 2013;11(2):63-71</RefSource>
<PMID Version="1">23038208</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacol Rev. 2013 Jan;65(1):171-222</RefSource>
<PMID Version="1">23319549</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuropharmacology. 2013 Apr;67:243-51</RefSource>
<PMID Version="1">23196068</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2013 Jan;28(1):41-50</RefSource>
<PMID Version="1">22791686</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sci Rep. 2013;3:1447</RefSource>
<PMID Version="1">23486177</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Neurol. 2013 May;9(5):248-56</RefSource>
<PMID Version="1">23588357</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 2013 Aug;246:72-83</RefSource>
<PMID Version="1">22285449</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>ACS Chem Neurosci. 2013 May 15;4(5):680-92</RefSource>
<PMID Version="1">23541043</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>ACS Chem Neurosci. 2013 May 15;4(5):648-51</RefSource>
<PMID Version="1">23862751</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2013 Jul;28(8):1058-63</RefSource>
<PMID Version="1">23389938</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurotox Res. 2014 Jan;25(1):13-23</RefSource>
<PMID Version="1">24155156</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sci Rep. 2014;4:3730</RefSource>
<PMID Version="1">24429495</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2014 Feb;13(2):141-9</RefSource>
<PMID Version="1">24361112</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2014 Feb 28;260:73-86</RefSource>
<PMID Version="1">24361918</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Front Neural Circuits. 2014;8:21</RefSource>
<PMID Version="1">24672433</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4578-83</RefSource>
<PMID Version="1">24599591</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Commun. 2014;5:3633</RefSource>
<PMID Version="1">24736453</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2014 Jun 11;34(24):8210-8</RefSource>
<PMID Version="1">24920625</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9977-82</RefSource>
<PMID Version="1">24979780</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacol Ther. 2014 Dec;144(3):268-82</RefSource>
<PMID Version="1">24945828</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Pharmacol. 2013 Nov;170(5):999-1013</RefSource>
<PMID Version="1">23992249</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2001 Aug 15;21(16):5916-24</RefSource>
<PMID Version="1">11487614</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2001 Aug;50(2):254-7</RefSource>
<PMID Version="1">11506410</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2002 Sep 15;22(18):8002-9</RefSource>
<PMID Version="1">12223553</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Hum Mol Genet. 2002 Oct 1;11(20):2395-407</RefSource>
<PMID Version="1">12351575</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2002 Oct 15;22(20):8951-60</RefSource>
<PMID Version="1">12388602</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res. 2003 Apr 18;969(1-2):135-46</RefSource>
<PMID Version="1">12676374</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2003 Aug 27;23(21):7917-21</RefSource>
<PMID Version="1">12944522</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2003 Dec;87(5):1284-95</RefSource>
<PMID Version="1">14622108</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurotoxicology. 2004 Jan;25(1-2):101-15</RefSource>
<PMID Version="1">14697885</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Nov 14;67(9):1612-7</RefSource>
<PMID Version="1">17101892</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2007 Jul;130(Pt 7):1819-33</RefSource>
<PMID Version="1">17452372</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2007 Jul 25;27(30):8138-48</RefSource>
<PMID Version="1">17652604</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurosci Res. 2007 Sep;59(1):1-7</RefSource>
<PMID Version="1">17586078</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2008 Jun;131(Pt 6):1574-87</RefSource>
<PMID Version="1">18487277</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res Rev. 2008 Aug;58(2):303-13</RefSource>
<PMID Version="1">18433875</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>CNS Neurosci Ther. 2008 Winter;14(4):340-51</RefSource>
<PMID Version="1">19040557</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mol Neurobiol. 2009 Apr;39(2):149-70</RefSource>
<PMID Version="1">19259829</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuron. 2009 Apr 30;62(2):218-29</RefSource>
<PMID Version="1">19409267</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Synapse. 2009 Jul;63(7):610-20</RefSource>
<PMID Version="1">19309758</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Exp Neurol. 2009 Sep;219(1):298-307</RefSource>
<PMID Version="1">19500572</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2010 Apr;38(1):136-43</RefSource>
<PMID Version="1">20096781</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2010 Mar;112(6):1465-76</RefSource>
<PMID Version="1">20050978</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13159-64</RefSource>
<PMID Version="1">20615977</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Prog Brain Res. 2010;183:59-77</RefSource>
<PMID Version="1">20696315</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Prog Brain Res. 2010;183:209-33</RefSource>
<PMID Version="1">20696322</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2010 Nov;68(5):619-28</RefSource>
<PMID Version="1">20882603</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pharmacol Exp Ther. 2010 Dec;335(3):743-53</RefSource>
<PMID Version="1">20858707</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2011 Feb;41(2):585-90</RefSource>
<PMID Version="1">21092759</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuron. 2011 Feb 24;69(4):628-49</RefSource>
<PMID Version="1">21338876</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Physiol. 2011 Mar 15;589(Pt 6):1349-66</RefSource>
<PMID Version="1">21242252</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2011 Apr 27;31(17):6605-15</RefSource>
<PMID Version="1">21525301</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Med Res Rev. 2011 Jul;31(4):483-519</RefSource>
<PMID Version="1">20135628</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2011 Dec 15;198:245-51</RefSource>
<PMID Version="1">21840375</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2000 Jan;74(1):263-9</RefSource>
<PMID Version="1">10617128</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 2000 Feb 1;39(4):773-8</RefSource>
<PMID Version="1">10651643</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2000 Mar;74(3):1086-97</RefSource>
<PMID Version="1">10693940</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Rev Neurosci. 2000;11(2-3):159-212</RefSource>
<PMID Version="1">10718152</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2000 Apr;47(4 Suppl 1):S2-9; discussion S9-11</RefSource>
<PMID Version="1">10762127</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2000 Apr;47(4 Suppl 1):S160-4; discussion S164-6</RefSource>
<PMID Version="1">10762144</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):11869-74</RefSource>
<PMID Version="1">11050221</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell Transplant. 2000 Sep-Oct;9(5):567-76</RefSource>
<PMID Version="1">11144954</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Neurosci. 2001 Feb;13(4):773-80</RefSource>
<PMID Version="1">11207812</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 2004 Apr;7(4):341-6</RefSource>
<PMID Version="1">14990933</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2004 Sep;19(9):997-1005</RefSource>
<PMID Version="1">15372588</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1967 Feb 16;276(7):374-9</RefSource>
<PMID Version="1">5334614</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Pharm Pharmacol. 1970 Apr;22(4):313-6</RefSource>
<PMID Version="1">4392579</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Science. 1971 Apr 30;172(3982):487-9</RefSource>
<PMID Version="1">5550505</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 1980 Feb 21;283(5749):772-4</RefSource>
<PMID Version="1">6101905</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 1984 Dec;13(4):1189-215</RefSource>
<PMID Version="1">6152036</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 1989 May 22;100(1-3):29-34</RefSource>
<PMID Version="1">2761778</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 1990;604:323-43</RefSource>
<PMID Version="1">2171398</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1990 Aug 13;525(1):36-44</RefSource>
<PMID Version="1">2123121</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10754-8</RefSource>
<PMID Version="1">1961743</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 1992 Nov 23;147(1):53-7</RefSource>
<PMID Version="1">1480324</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1993 Nov;34(5):638-45</RefSource>
<PMID Version="1">7902065</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Naunyn Schmiedebergs Arch Pharmacol. 1994 Jul;350(1):15-21</RefSource>
<PMID Version="1">7935849</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1994 Dec 26;667(2):295-9</RefSource>
<PMID Version="1">7697371</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 1998 May;43(5):555-60</RefSource>
<PMID Version="1">9585349</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 1998 Jun 1;18(11):4106-18</RefSource>
<PMID Version="1">9592091</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Physiol. 1998 Jul;275(1 Pt 1):C104-12</RefSource>
<PMID Version="1">9688840</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1999 Jan 30;817(1-2):185-91</RefSource>
<PMID Version="1">9889362</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1999 Apr;72(4):1516-22</RefSource>
<PMID Version="1">10098856</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuroreport. 1999 Feb 25;10(3):631-4</RefSource>
<PMID Version="1">10208602</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trends Pharmacol Sci. 1999 Apr;20(4):142-50</RefSource>
<PMID Version="1">10322499</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacol Rev. 1952 Dec;4(4):415-58</RefSource>
<PMID Version="1">13026407</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Wien Klin Wochenschr. 1961 Nov 10;73:787-8</RefSource>
<PMID Version="1">13869404</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain. 2004 Dec;127(Pt 12):2747-54</RefSource>
<PMID Version="1">15329355</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurosci Res. 2005 Jun;52(2):185-94</RefSource>
<PMID Version="1">15893579</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2006;139(3):1005-15</RefSource>
<PMID Version="1">16542784</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2006 Jun;22(3):586-98</RefSource>
<PMID Version="1">16531050</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2006 Aug;5(8):677-87</RefSource>
<PMID Version="1">16857573</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2006 Sep 6;26(36):9304-11</RefSource>
<PMID Version="1">16957086</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2006 Oct;99(2):381-92</RefSource>
<PMID Version="1">16942598</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2001;103(3):639-51</RefSource>
<PMID Version="1">11274784</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2001 May;16(3):448-58</RefSource>
<PMID Version="1">11391738</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Mol Neurosci. 1994 Fall;5(3):149-64</RefSource>
<PMID Version="1">7654518</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 1995 Sep;15(9):6179-88</RefSource>
<PMID Version="1">7666200</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1996 Feb;66(2):629-36</RefSource>
<PMID Version="1">8592133</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1996 May 14;93(10):5166-71</RefSource>
<PMID Version="1">8643547</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurology. 1996 May;46(5):1430-6</RefSource>
<PMID Version="1">8628494</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 1996 Jul 1;16(13):4135-45</RefSource>
<PMID Version="1">8753875</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1995 Dec 15;704(1):51-60</RefSource>
<PMID Version="1">8750961</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurocytol. 1996 Dec;25(12):843-56</RefSource>
<PMID Version="1">9023729</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 1997;4(3-4):247-53</RefSource>
<PMID Version="1">9361301</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neuron. 1997 Dec;19(6):1271-83</RefSource>
<PMID Version="1">9427250</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):4029-34</RefSource>
<PMID Version="1">9520487</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 1998 May;70(5):1973-8</RefSource>
<PMID Version="1">9572281</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004298">Dopamine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009474">Neurons</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000166">cytology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D017729">Presynaptic Terminals</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS641575 [Available on 01/01/16]</OtherID>
<OtherID Source="NLM">PMC4314471 [Available on 01/01/16]</OtherID>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's Disease</Keyword>
<Keyword MajorTopicYN="N">dopamine</Keyword>
<Keyword MajorTopicYN="N">dyskinesia</Keyword>
<Keyword MajorTopicYN="N">levodopa</Keyword>
<Keyword MajorTopicYN="N">presynaptic</Keyword>
<Keyword MajorTopicYN="N">serotonin</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>8</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>11</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="aheadofprint"><Year>2014</Year>
<Month>12</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>12</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>12</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>9</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pmc-release"><Year>2016</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25450307</ArticleId>
<ArticleId IdType="doi">10.1002/mds.26103</ArticleId>
<ArticleId IdType="pmc">PMC4314471</ArticleId>
<ArticleId IdType="mid">NIHMS641575</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>État de New York</li>
</region>
</list>
<tree><noCountry><name sortKey="Borgkvist, Anders" sort="Borgkvist, Anders" uniqKey="Borgkvist A" first="Anders" last="Borgkvist">Anders Borgkvist</name>
<name sortKey="Sulzer, David" sort="Sulzer, David" uniqKey="Sulzer D" first="David" last="Sulzer">David Sulzer</name>
</noCountry>
<country name="États-Unis"><region name="État de New York"><name sortKey="Mosharov, Eugene V" sort="Mosharov, Eugene V" uniqKey="Mosharov E" first="Eugene V" last="Mosharov">Eugene V. Mosharov</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000109 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000109 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:25450307
   |texte=   Presynaptic effects of levodopa and their possible role in dyskinesia.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:25450307" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Presynaptic effects of levodopa and their possible role in dyskinesia.

Presynaptic effects of levodopa and their possible role in dyskinesia.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki